{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "USD", "marketState": "POSTPOST", "regularMarketPrice": 12.12, "exchange": "LSE", "shortName": "UROGEN PHARMA LTD UROGEN PHARMA", "longName": "UroGen Pharma Ltd.", "messageBoardId": "finmb_240702165", "exchangeTimezoneName": "Europe/London", "exchangeTimezoneShortName": "BST", "gmtOffSetMilliseconds": 3600000, "market": "gb_market", "esgPopulated": false, "regularMarketChangePercent": -8.872183, "firstTradeDateMilliseconds": 1545379200000, "priceHint": 2, "regularMarketChange": -1.1800003, "regularMarketTime": 1683828867, "regularMarketDayHigh": 0.0, "regularMarketDayRange": "0.0 - 0.0", "regularMarketDayLow": 0.0, "regularMarketVolume": 8000, "regularMarketPreviousClose": 13.3, "bid": 0.0, "ask": 0.0, "fullExchangeName": "LSE", "financialCurrency": "USD", "regularMarketOpen": 0.0, "averageDailyVolume3Month": 2608, "averageDailyVolume10Day": 4550, "fiftyTwoWeekLowChange": 12.12, "fiftyTwoWeekRange": "0.0 - 13.75", "fiftyTwoWeekHighChange": -1.6300001, "fiftyTwoWeekHighChangePercent": -0.118545465, "fiftyTwoWeekLow": 0.0, "fiftyTwoWeekHigh": 13.75, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -5.047, "sharesOutstanding": 16102300, "bookValue": -3.863, "fiftyDayAverage": 9.7837715, "fiftyDayAverageChange": 2.3362284, "fiftyDayAverageChangePercent": 0.23878607, "twoHundredDayAverage": 9.7837715, "twoHundredDayAverageChange": 2.3362284, "twoHundredDayAverageChangePercent": 0.23878607, "marketCap": 1696145, "priceToBook": -3.137458, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "symbol": "0XOD.L"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "400 Alexander Park", "city": "Princeton", "state": "NJ", "zip": "08540", "country": "United States", "phone": "646 768 9780", "website": "https://www.urogen.com", "industry": "", "sector": "", "longBusinessSummary": "UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for NMIBC. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.", "fullTimeEmployees": 200, "companyOfficers": [{"maxAge": 1, "name": "Ms. Elizabeth A. Barrett", "age": 60, "title": "Pres, CEO & Director", "yearBorn": 1962, "fiscalYear": 2022, "totalPay": {"raw": 1117365, "fmt": "1.12M", "longFmt": "1,117,365"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Dong  Kim", "age": 45, "title": "Chief Financial Officer", "yearBorn": 1977, "fiscalYear": 2022, "totalPay": {"raw": 546685, "fmt": "546.68k", "longFmt": "546,685"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Jason Drew Smith", "age": 50, "title": "Gen. Counsel, Chief Compliance Officer & Corp. Sec.", "yearBorn": 1972, "fiscalYear": 2022, "totalPay": {"raw": 717582, "fmt": "717.58k", "longFmt": "717,582"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Vincent I. Perrone", "title": "Sr. Director of Investor Relations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Eric  Van Zanten", "title": "Sr. Director of Communications", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Sari  Prutchi-Sagiv Ph.D.", "title": "Marketing Director", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Marina  Konorty", "title": "Exec. VP of R&D and Technical Operations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Mark P. Schoenberg M.D.", "age": 64, "title": "Chief Medical Officer", "yearBorn": 1958, "fiscalYear": 2021, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Jeffrey  Bova M.B.A.", "title": "Chief Commercial Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. James  Ottinger R.ph.", "title": "Exec. VP of Regulatory Affairs & Quality", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 8, "boardRisk": 3, "compensationRisk": 10, "shareHolderRightsRisk": 1, "overallRisk": 6, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}